Management of chronic heart failure : state of the art according to the 2021 guideline
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Treatment of heart failure with reduced ejection fraction (HFrEF) requires four drug classes that should be initiated simultaneously and up-titrated rapidly. All four have received class I recommendations. Sacubitril/valsartan can be considered in initial treatment, even for patients in whom no previous treatment with an angiotensin converting enzyme inhibitor has been given. Treatment with dapagliflozin and empagliflozin is started irrespective of diabetes mellitus to reduce mortality and hospitalization rates for heart failure. Most drug treatment recommendations for HFrEF can be extrapolated to heart failure with mildly-reduced ejection fraction, even though the evidence base is not as robust as in HFrEF. Treatment individualization considers co-morbidities such as atrial fibrillation, valvular disease and iron deficiency as well as advanced heart failure. Following cardiac decompensation, verciguat is now available as an additional treatment option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Innere Medizin (Heidelberg, Germany) - 63(2022), 11 vom: 01. Nov., Seite 1148-1160 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Therapie der chronischen Herzinsuffizienz – State of the Art nach den europäischen Leitlinien von 2021 |
|---|
| Beteiligte Personen: |
Hellenkamp, Kristian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.10.2022 Date Revised 28.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00108-022-01394-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346419875 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346419875 | ||
| 003 | DE-627 | ||
| 005 | 20231226031417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00108-022-01394-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346419875 | ||
| 035 | |a (NLM)36125514 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Hellenkamp, Kristian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of chronic heart failure |b state of the art according to the 2021 guideline |
| 246 | 3 | 3 | |a Therapie der chronischen Herzinsuffizienz – State of the Art nach den europäischen Leitlinien von 2021 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2022 | ||
| 500 | |a Date Revised 28.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Treatment of heart failure with reduced ejection fraction (HFrEF) requires four drug classes that should be initiated simultaneously and up-titrated rapidly. All four have received class I recommendations. Sacubitril/valsartan can be considered in initial treatment, even for patients in whom no previous treatment with an angiotensin converting enzyme inhibitor has been given. Treatment with dapagliflozin and empagliflozin is started irrespective of diabetes mellitus to reduce mortality and hospitalization rates for heart failure. Most drug treatment recommendations for HFrEF can be extrapolated to heart failure with mildly-reduced ejection fraction, even though the evidence base is not as robust as in HFrEF. Treatment individualization considers co-morbidities such as atrial fibrillation, valvular disease and iron deficiency as well as advanced heart failure. Following cardiac decompensation, verciguat is now available as an additional treatment option | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Heart failure, mildly reduced ejection fraction | |
| 650 | 4 | |a Heart failure, preserved ejection fraction | |
| 650 | 4 | |a Heart failure, reduced ejection fraction | |
| 650 | 4 | |a Heart failure/comorbidity | |
| 650 | 4 | |a Heart failure/drug therapy | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Tetrazoles |2 NLM | |
| 650 | 7 | |a Valsartan |2 NLM | |
| 650 | 7 | |a 80M03YXJ7I |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 700 | 1 | |a Valentova, Miroslava |e verfasserin |4 aut | |
| 700 | 1 | |a von Haehling, Stephan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Innere Medizin (Heidelberg, Germany) |d 2022 |g 63(2022), 11 vom: 01. Nov., Seite 1148-1160 |w (DE-627)NLM33707271X |x 2731-7099 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:11 |g day:01 |g month:11 |g pages:1148-1160 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00108-022-01394-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 11 |b 01 |c 11 |h 1148-1160 | ||